Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2-Associated Acute Respiratory Failure
CONCLUSION AND RELEVANCE: In the first published report of its use within this population, bivalirudin was found to be a viable choice for anticoagulation in those patients on ECMO for severe respiratory failure secondary to COVID-19.PMID:34323121 | DOI:10.1177/10600280211036151
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Brittany D Bissell Taylor Gabbard Erica A Sheridan Maher A Baz George A Davis Ayesha Ather Source Type: research
More News: Angiomax | Bleeding | COVID-19 | Drugs & Pharmacology | Respiratory Medicine | SARS | Study